Pharmacyclics, Inc. (PCYC) Tops Q1 EPS Views; Updates on IMBRUVICA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Downgrades Pharmacyclics (PCYC) to Neutral
May 2, 2014 10:56 AM EDTPiper Jaffray downgraded Pharmacyclics (NASDAQ: PCYC) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $95.21 yesterday.
... MorePharmacyclics, Inc. (PCYC) trading halted with news pending
May 2, 2014 7:56 AM EDTPharmacyclics, Inc. (NASDAQ: PCYC) trading halted with news pending.
... More